MX354024B - Uso de array-380 y ar00440993 para el tratamiento de cancer de cerebro. - Google Patents
Uso de array-380 y ar00440993 para el tratamiento de cancer de cerebro.Info
- Publication number
- MX354024B MX354024B MX2014011437A MX2014011437A MX354024B MX 354024 B MX354024 B MX 354024B MX 2014011437 A MX2014011437 A MX 2014011437A MX 2014011437 A MX2014011437 A MX 2014011437A MX 354024 B MX354024 B MX 354024B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- brain cancer
- compounds
- pharmaceutical compositions
- brain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente se proporcionan compuestos para el tratamiento de cáncer de cerebro. También se proporcionan en la presente composiciones farmacéuticas comprendidas de estos compuestos para el tratamiento de cáncer de cerebro.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261615082P | 2012-03-23 | 2012-03-23 | |
PCT/US2013/033751 WO2013142875A1 (en) | 2012-03-23 | 2013-03-25 | Treatment of brain cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014011437A MX2014011437A (es) | 2014-11-10 |
MX354024B true MX354024B (es) | 2018-02-08 |
Family
ID=48048296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014011437A MX354024B (es) | 2012-03-23 | 2013-03-25 | Uso de array-380 y ar00440993 para el tratamiento de cancer de cerebro. |
Country Status (30)
Country | Link |
---|---|
US (3) | US20150110780A1 (es) |
EP (4) | EP4252855A3 (es) |
JP (6) | JP2015514075A (es) |
KR (3) | KR102317166B1 (es) |
CN (2) | CN104203279B (es) |
AU (4) | AU2013234921A1 (es) |
CA (1) | CA2867723C (es) |
CL (1) | CL2014002497A1 (es) |
CO (1) | CO7071139A2 (es) |
CY (2) | CY1120204T1 (es) |
DK (2) | DK2827900T3 (es) |
ES (2) | ES2673165T3 (es) |
HK (1) | HK1206276A1 (es) |
HR (1) | HRP20180659T1 (es) |
HU (2) | HUE037966T2 (es) |
IL (3) | IL234627B (es) |
LT (1) | LT2827900T (es) |
MX (1) | MX354024B (es) |
MY (2) | MY202114A (es) |
NZ (4) | NZ756264A (es) |
PH (1) | PH12014502032A1 (es) |
PL (2) | PL3400943T3 (es) |
PT (2) | PT3400943T (es) |
RS (1) | RS57140B1 (es) |
RU (2) | RU2018138976A (es) |
SG (1) | SG11201405954YA (es) |
SI (2) | SI2827900T1 (es) |
TR (1) | TR201808450T4 (es) |
UA (1) | UA122044C2 (es) |
WO (1) | WO2013142875A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2765990B1 (en) | 2011-10-14 | 2017-09-06 | Array Biopharma, Inc. | Solid dispersion |
SG11201401460PA (en) | 2011-10-14 | 2014-09-26 | Array Biopharma Inc | POLYMORPHS OF ARRY-380, A SELECTIVE ErbB2 (HER2) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO2013142875A1 (en) | 2012-03-23 | 2013-09-26 | Array Biopharma Inc. | Treatment of brain cancer |
WO2018165015A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
WO2018201016A1 (en) | 2017-04-28 | 2018-11-01 | Cascadian Therapeutics, Inc. | Treatment of her2 positive cancers |
CA3089566A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
EP3773726A1 (en) * | 2018-04-09 | 2021-02-17 | Moshe Giladi | Treating tumors with ttfields and an aurora kinase inhibitor |
CN109942576B (zh) * | 2019-03-07 | 2020-09-11 | 上海工程技术大学 | Irbinitinib及中间体的制备方法 |
CN111825604A (zh) * | 2019-04-16 | 2020-10-27 | 宁波药腾医药科技有限公司 | 一种图卡替尼及其中间产物的合成方法 |
JP2022544234A (ja) | 2019-08-12 | 2022-10-17 | デシフェラ・ファーマシューティカルズ,エルエルシー | 胃腸間質腫瘍を治療するためのリプレチニブ |
KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
EP4084778B1 (en) * | 2019-12-30 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Amorphous kinase inhibitor formulations and methods of use thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH690163A5 (fr) * | 1995-07-28 | 2000-05-31 | Symphar Sa | Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers. |
US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
RU2255765C2 (ru) * | 2000-01-21 | 2005-07-10 | Чилдренз Хоспитал Лос-Анджелес | Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов |
US20020137731A1 (en) | 2000-05-30 | 2002-09-26 | Gewirtz David A. | Combination of radiation and vitamin D3 analogs for the treatment of cancer |
DK1660090T3 (da) | 2003-08-14 | 2012-12-17 | Array Biopharma Inc | Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer |
CN1989112A (zh) * | 2004-06-03 | 2007-06-27 | 史密丝克莱恩比彻姆(科克)有限公司 | 癌症治疗方法 |
AU2005251722B2 (en) | 2004-06-03 | 2009-11-12 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
EP1971601B1 (en) * | 2005-11-15 | 2009-10-21 | Array Biopharma Inc. | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
AU2007235199B8 (en) | 2006-01-31 | 2010-10-28 | Novartis Ag | IL-17 antagonistic antibodies for treating cancer |
US20120052061A1 (en) * | 2007-09-24 | 2012-03-01 | Tragara Pharmaceuticals Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
HUE025507T2 (en) * | 2008-03-18 | 2016-02-29 | Genentech Inc | Combinations of anti-HER2 antibody-drug conjugate and chemotherapeutic agents and methods for their use |
EP2765990B1 (en) | 2011-10-14 | 2017-09-06 | Array Biopharma, Inc. | Solid dispersion |
SG11201401460PA (en) | 2011-10-14 | 2014-09-26 | Array Biopharma Inc | POLYMORPHS OF ARRY-380, A SELECTIVE ErbB2 (HER2) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO2013142875A1 (en) | 2012-03-23 | 2013-09-26 | Array Biopharma Inc. | Treatment of brain cancer |
-
2013
- 2013-03-25 WO PCT/US2013/033751 patent/WO2013142875A1/en active Application Filing
- 2013-03-25 PL PL18162971T patent/PL3400943T3/pl unknown
- 2013-03-25 CN CN201380015856.XA patent/CN104203279B/zh active Active
- 2013-03-25 DK DK13714497.8T patent/DK2827900T3/en active
- 2013-03-25 PL PL13714497T patent/PL2827900T3/pl unknown
- 2013-03-25 NZ NZ756264A patent/NZ756264A/en unknown
- 2013-03-25 UA UAA201411479A patent/UA122044C2/uk unknown
- 2013-03-25 CA CA2867723A patent/CA2867723C/en active Active
- 2013-03-25 SI SI201331019T patent/SI2827900T1/en unknown
- 2013-03-25 PT PT181629718T patent/PT3400943T/pt unknown
- 2013-03-25 KR KR1020207027176A patent/KR102317166B1/ko active IP Right Grant
- 2013-03-25 EP EP23163332.2A patent/EP4252855A3/en active Pending
- 2013-03-25 HU HUE13714497A patent/HUE037966T2/hu unknown
- 2013-03-25 KR KR1020147029340A patent/KR102160462B1/ko active IP Right Grant
- 2013-03-25 ES ES13714497.8T patent/ES2673165T3/es active Active
- 2013-03-25 MY MYPI2019003395A patent/MY202114A/en unknown
- 2013-03-25 DK DK18162971.8T patent/DK3400943T3/da active
- 2013-03-25 JP JP2015501952A patent/JP2015514075A/ja active Pending
- 2013-03-25 TR TR2018/08450T patent/TR201808450T4/tr unknown
- 2013-03-25 NZ NZ74161513A patent/NZ741615A/en unknown
- 2013-03-25 EP EP18162971.8A patent/EP3400943B1/en active Active
- 2013-03-25 AU AU2013234921A patent/AU2013234921A1/en not_active Abandoned
- 2013-03-25 SI SI201331844T patent/SI3400943T1/sl unknown
- 2013-03-25 ES ES18162971T patent/ES2855142T3/es active Active
- 2013-03-25 SG SG11201405954YA patent/SG11201405954YA/en unknown
- 2013-03-25 EP EP20210661.3A patent/EP3842044A1/en not_active Withdrawn
- 2013-03-25 RS RS20180484A patent/RS57140B1/sr unknown
- 2013-03-25 LT LTEP13714497.8T patent/LT2827900T/lt unknown
- 2013-03-25 NZ NZ724544A patent/NZ724544A/en unknown
- 2013-03-25 HU HUE18162971A patent/HUE053156T2/hu unknown
- 2013-03-25 US US14/387,533 patent/US20150110780A1/en not_active Abandoned
- 2013-03-25 PT PT137144978T patent/PT2827900T/pt unknown
- 2013-03-25 NZ NZ630843A patent/NZ630843A/en unknown
- 2013-03-25 EP EP13714497.8A patent/EP2827900B1/en active Active
- 2013-03-25 MX MX2014011437A patent/MX354024B/es active IP Right Grant
- 2013-03-25 CN CN201811150918.9A patent/CN109223791A/zh active Pending
- 2013-03-25 RU RU2018138976A patent/RU2018138976A/ru unknown
- 2013-03-25 KR KR1020217033686A patent/KR102490961B1/ko active IP Right Grant
- 2013-03-25 RU RU2014142700A patent/RU2672575C2/ru active
- 2013-03-25 MY MYPI2014702686A patent/MY174883A/en unknown
-
2014
- 2014-09-12 PH PH12014502032A patent/PH12014502032A1/en unknown
- 2014-09-14 IL IL234627A patent/IL234627B/en active IP Right Grant
- 2014-09-19 CO CO14208829A patent/CO7071139A2/es unknown
- 2014-09-22 CL CL2014002497A patent/CL2014002497A1/es unknown
-
2015
- 2015-07-23 HK HK15107019.5A patent/HK1206276A1/xx unknown
-
2017
- 2017-05-25 JP JP2017103957A patent/JP2017141302A/ja active Pending
- 2017-12-06 AU AU2017272232A patent/AU2017272232C1/en active Active
-
2018
- 2018-04-25 HR HRP20180659TT patent/HRP20180659T1/hr unknown
- 2018-05-14 CY CY20181100493T patent/CY1120204T1/el unknown
- 2018-09-06 IL IL261659A patent/IL261659A/en unknown
-
2019
- 2019-02-27 JP JP2019034250A patent/JP6898960B2/ja active Active
- 2019-05-02 US US16/402,068 patent/US11504370B2/en active Active
- 2019-05-23 AU AU2019203618A patent/AU2019203618B2/en active Active
- 2019-09-09 IL IL269205A patent/IL269205B/en active IP Right Grant
-
2021
- 2021-02-16 CY CY20211100126T patent/CY1123837T1/el unknown
- 2021-06-11 JP JP2021097676A patent/JP2021178820A/ja active Pending
- 2021-11-01 AU AU2021261849A patent/AU2021261849A1/en not_active Abandoned
-
2022
- 2022-10-28 US US17/975,709 patent/US20230190749A1/en active Pending
- 2022-11-04 JP JP2022177278A patent/JP7404485B2/ja active Active
-
2023
- 2023-12-13 JP JP2023209972A patent/JP2024019526A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014502032A1 (en) | Treatment of brain cancer | |
HRP20190046T1 (hr) | Kombinirana terapija za liječenje raka | |
HK1207861A1 (en) | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 | |
PT2818482T (pt) | Composição farmacêutica para o tratamento de cancro | |
HUE045461T2 (hu) | Gyógyászati készítmény rák kezelésére | |
HK1206338A1 (en) | Pyrimidine compounds for the treatment of cancer | |
MX2015007097A (es) | Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer. | |
EP2925752A4 (en) | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT | |
EP2830633A4 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
GB201322626D0 (en) | Combined preparations for the treatment of cancer | |
HK1219737A1 (zh) | 用於治療癌症的新化合物 | |
HK1222548A1 (zh) | 治療惡性腫瘤的藥物組合 | |
HK1215794A1 (zh) | 用於治療疾病的同種異體自噬體富集組合物 | |
EP3003489A4 (en) | Cytotoxic agents for the treatment of cancer | |
MX2013014488A (es) | Metodos y composiciones para tratar el cancer cerebral. | |
WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
GEP201706636B (en) | Galactagogue compositions based on phosphatidylserine | |
IN2013MU03118A (es) | ||
PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
EP3242681B8 (en) | Novel compounds for the treatment of cancer | |
EP3285763A4 (en) | Compositions for the treatment of cancer | |
MX351961B (es) | Analogos de diazonamida. | |
IN2013DE03665A (es) | ||
MX2015001134A (es) | Compuestos terapeuticos. | |
HK1209111A1 (zh) | 醌系化合物及其用於癌症治療的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |